ondasdechoque.org
PT-BR

Osteonecrosis of the femoral head · Review · 2025

Does shockwave help early osteonecrosis of the hip?

In this review of 9 studies, people with early osteonecrosis of the hip had less pain and better hip function after shockwave. In 4 studies, average pain fell from above 5 to about 1. The damaged area on scans did not clearly shrink.

Improved over time
studies
9
patients reported in total
716
studies measured hip function before and after
5

Good to know: The pooled results compare people before and after shockwave, not with another treatment.

Tan H, Tang P, Chai H, et al. International Journal of Surgery (London, England), 2025 · Read the paper ↗

How this study worked

One answer
A review gathers earlier studies to answer one question. Illustration, not to scale.

Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.

What the trials used

ESWT regimens
Table 2 reports pulse counts per study; the review does not say whether focused or radial devices were used. Available pulse counts include 1,500, 2,000, 2,400, 4,000 and 6,000; dosing fields are incomplete and vary by study.
Imaging guidance
The review discusses MRI/3D reconstruction, T2 localization and positioning to improve targeting of necrotic areas; not all included studies used the same imaging method.

Who took part

People with early osteonecrosis of the hip in 9 studies, including trials and case series; some studies counted hips rather than people.

Side effects

The review did not pool side effects; the authors say long-term effects need more study.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Nine studies of early femoral-head osteonecrosis, reported as 716 patients, including randomized studies and case series. Some table samples are hips rather than clearly stated participants.

Harris Hip Score1 reported outcome
01
Pretreatment versus post-treatment; follow-up varies by study

Harris Hip Score

Harris Hip Score Mean difference as reported; source units/direction unclear

MD-33.38CI 95% -46.31 to -20.45p <0.00001

Within-ESWT pre–post synthesis; not an ESWT versus control comparison

5 studies · I²=96%

-51.9Equal results 05.6

Reported estimate and confidence interval.

A pre–post synthesis of five studies and 146 hips reported MD −33.38 (95% CI −46.31 to −20.45; p<0.00001; I²=96%). This is not an ESWT-versus-control effect; the review says HHS increased but the sign convention for its MD is not explained.

Analysis details and source

The review could not conduct standardized ESWT-versus-control meta-analysis. These are uncontrolled pre–post changes; scale/range or direction limitations are retained.

Pain (VAS)1 reported outcome
02
Pretreatment versus post-treatment; follow-up varies by study

Pain (VAS)

Pain (VAS) Mean difference as reported; source units/direction unclear

MD4.64CI 95% 3.63 to 5.64p <0.0001

Within-ESWT pre–post synthesis; not an ESWT versus control comparison

4 studies · I²=86%

-0.7Equal results 06.3

Reported estimate and confidence interval.

A pre–post synthesis of four studies and 126 patients reported MD 4.64 (95% CI 3.63–5.64; p<0.0001; I²=86%), with mean score described as falling from above 4 to about 2. The VAS range and sign coding for the reported MD are not stated. The source is inconsistent: the same Results paragraph also prints P<0.00001, and the Abstract says the average VAS was above 5 before treatment and dropped to 1.2 (P<0.00001); the values stored here are those in the Results parenthesis.

Analysis details and source

The review could not conduct standardized ESWT-versus-control meta-analysis. These are uncontrolled pre–post changes; scale/range or direction limitations are retained.

Imaging lesion size1 reported outcome
03
Pretreatment versus post-treatment; follow-up varies by study

Imaging lesion size

Mean difference as reported; source units/direction unclear

MD6.75CI 95% -0.14 to 13.64p = 0.06

Within-ESWT pre–post synthesis; not an ESWT versus control comparison

3 studies · I²=75%

-1.8Equal results 015.3

Reported estimate and confidence interval.

Three studies, five groups and 142 persons contributed. The reported pre–post MD was 6.75 (95% CI −0.14 to 13.64; p=.06; I²=75%); authors say no significant reduction in necrotic area. Units/direction are not clear in the text. The Abstract prints different figures for this analysis (MD 9.66; 95% CI −0.36 to 19.67; P=0.06; I²=84%); the values stored here are those in the Results section.

Analysis details and source

The review could not conduct standardized ESWT-versus-control meta-analysis. These are uncontrolled pre–post changes; scale/range or direction limitations are retained.

ARCO stage1 reported outcome
04
Pretreatment versus post-treatment; follow-up varies by study

ARCO stage

Mean difference as reported; source units/direction unclear

MD1.11CI 95% 0.76 to 1.62p = 0.60

Within-ESWT pre–post synthesis; not an ESWT versus control comparison

2 studies · I²=0%

-0.2Equal results 01.8

Reported estimate and confidence interval.

Two articles contributed to a pre–post fixed-effect analysis: MD 1.11 (95% CI 0.76–1.62; p=.60; I²=0%). The paper reports no significant change; the reported estimate/CI/p combination is internally inconsistent because the interval excludes the null while p is nonsignificant.

Analysis details and source

The review could not conduct standardized ESWT-versus-control meta-analysis. These are uncontrolled pre–post changes; scale/range or direction limitations are retained.

Bone-marrow-edema grade1 reported outcome
05
Pretreatment versus post-treatment; follow-up varies by study

Bone-marrow-edema grade

Mean difference as reported; source units/direction unclear

MD4.35CI 95% 1.32 to 14.37p = 0.02

Within-ESWT pre–post synthesis; not an ESWT versus control comparison

3 studies · I²=62%

-1.7Equal results 016.1

Reported estimate and confidence interval.

Three articles contributed 79 hips; random-effects MD 4.35 (95% CI 1.32–14.37; p=.02; I²=62%). The authors report significant improvement, but the outcome scale and direction for this unusually wide positive interval are not defined in the text.

Analysis details and source

The review could not conduct standardized ESWT-versus-control meta-analysis. These are uncontrolled pre–post changes; scale/range or direction limitations are retained.

How treatment was delivered
ESWT regimens

Table 2 reports pulse counts per study; the review does not say whether focused or radial devices were used. Available pulse counts include 1,500, 2,000, 2,400, 4,000 and 6,000; dosing fields are incomplete and vary by study.

Imaging guidance

The review discusses MRI/3D reconstruction, T2 localization and positioning to improve targeting of necrotic areas; not all included studies used the same imaging method.

HARMS & TOLERABILITY

No systematic pooled complication analysis was reported; the authors identify long-term complications as requiring further study.

LIMITS OF THE ANALYSIS

The review could not conduct standardized controlled meta-analysis and instead analyzed within-ESWT pre–post changes.

Included evidence mixes randomized studies and case series; some sample units are hips, and totals are not consistently reported.

Heterogeneity was high for HHS, VAS and lesion-size outcomes (I² 75–96%).

The ARCO meta-analysis reports MD 1.11, CI 0.76–1.62 and p=.60, an internally inconsistent estimate/interval/test.

The supplemental files (S1–S4 and the AMSTAR 2 assessment) and the primary studies were unavailable for independent verification of the review abstractions.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • The review could not conduct standardized controlled meta-analysis and instead analyzed within-ESWT pre–post changes.
  • Included evidence mixes randomized studies and case series; some sample units are hips, and totals are not consistently reported.
  • Heterogeneity was high for HHS, VAS and lesion-size outcomes (I² 75–96%).
  • The ARCO meta-analysis reports MD 1.11, CI 0.76–1.62 and p=.60, an internally inconsistent estimate/interval/test.
  • The supplemental files (S1–S4 and the AMSTAR 2 assessment) and the primary studies were unavailable for independent verification of the review abstractions.
Research review

Source-linked critical reading

Systematic review with before-after meta-analysis

Reading depthMaterial consulted
Technical source record

Complete full-text XML read with all raw tables and figure captions; the supplemental files (S1–S4 and the AMSTAR 2 assessment) and primary study reports were not retrieved.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Systematic review of nine studies (716 patients) including randomized studies and case series. The authors could not conduct a standardized ESWT-versus-control meta-analysis and instead pooled pre–post ESWT changes.

Participants

Early femoral-head osteonecrosis across ARCO stages and varied treatment contexts. Table 1 includes individual studies and reports hips for some cohorts; total participants/hips are not consistently distinguishable.

ESWT protocols and imaging

Table 2 reports ESWT at 1,500–6,000 pulses when available; the review does not say whether focused or radial devices were used. MRI/3D localization and positioning are discussed for targeting; pulse counts and treatment protocols vary, and several fields are unavailable.

Comparators

Some included studies compared ESWT with oral drugs or surgery, but the review could not pool standardized controlled contrasts because of insufficient comparable data.

Outcomes

Within-ESWT pre–post syntheses favored changes in HHS and VAS, both with very high heterogeneity. Imaging lesion size and ARCO stage were reported nonsignificant, while BME grade was reported significant. The ARCO estimate interval and p value conflict.

Between-group findings

These pooled values are pre–post associations and do not show that ESWT outperforms a comparator. The review includes case series and explicitly lacked sufficient standardized control data.

Harms

The review does not provide a systematic pooled complication analysis. Long-term complications are noted as needing further study.

Limitations

Small study samples, mixed randomized and case-series designs, short follow-up in some studies, substantial heterogeneity, no standardized comparator meta-analysis, inconsistent participant/hip reporting, and internally conflicting ARCO CI/p.

Applicability

The review supports imaging as a way to characterize early osteonecrosis and guide targeting, but does not establish imaging-guided ESWT superiority or prevent progression/arthroplasty.

What stronger evidence needs

Conduct larger controlled trials with clearly defined ARCO stage, patient versus hip unit, standardized imaging and clinical outcomes, consistent follow-up, complete complications reporting, and prespecified subgroup analyses.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shock wave therapy with imaging examination for early osteonecrosis of the femoral head: a systematic review.

Tan H, Tang P, Chai H, Ma W, Cao Y, Lin B, Zhu Y, Xiao W, Wen T, Li Y. · International journal of surgery (London, England) · 2025

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →